PROGENICS PHARMACEUTICALS INC
DelistedCIK 835887fmd_1EKQTFZACEFWEPB1Q29F4EF369Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Mar 31, 2020, 41 periods
| Line item | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 8 | 85 | 14 | 8 | 44 | 9 | 69 | 12 | 16 | 35 |
| Cost of revenue | – | – | – | – | – | – | – | – | – | 3 |
| Gross profit | – | – | – | – | – | – | – | – | – | 32 |
| Research and development | 51 | 53 | 31 | 35 | 29 | 28 | 38 | 43 | 35 | 49 |
| Selling, general and administrative | – | – | – | – | – | – | 23 | 25 | 29 | 48 |
| Total operating expenses | 78 | 74 | 50 | 51 | 48 | 48 | 56 | 70 | 82 | – |
| Operating income | (70) | 10 | (35) | (43) | 3 | (39) | 13 | (58) | (66) | (66) |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | – | – | – | – |
| Other non-operating income (expense) | 0 | 0 | 0 | 0 | 0 | 0 | (1) | (4) | (3) | (2) |
| Income before taxes | (70) | 10 | (35) | (43) | 3 | (39) | 13 | (63) | (69) | (69) |
| Income tax expense | (0) | 0 | 0 | (0) | (1) | (0) | 2 | (12) | (2) | 0 |
| Net income from continuing operations | (70) | 10 | (35) | (43) | 4 | (39) | 11 | (51) | (68) | (69) |
| Net income | (70) | 10 | (35) | (43) | 4 | (39) | 11 | (51) | (68) | (69) |
| Net income to common shareholders | – | 10 | – | – | 4 | – | 11 | – | – | – |